SAN DIEGO, Dec. 18, 2009 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market (Nasdaq:MNOV) and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today announced that it has completed its acquisition of Avigen, Inc. following approval of the transaction by each of MediciNova’s and Avigen’s stockholders yesterday. Completion of the transaction permits MediciNova to combine the companies’ broad neurological clinical development programs based on ibudilast (MediciNova’s MN-166 and Avigen’s AV411).
